Progress of the Food and Drug Administration in achieving the goals identified in the letters described in section 401(b) of the Biosimilar User Fee Amendments of 2022 during such fiscal year and the future plans of the Food and Drug Administration for meeting such goals
Citations are generated automatically from bibliographic data as a convenience and may not be complete or accurate.
Chicago
Food and Drug Administration, Health and Human Services Department.
"Performance Report to Congress: Biosimilar User Fee Act FY 2023". Government.
Health and Human Services Department, Food and Drug Administration,
April 19, 2024.
https://www.govinfo.gov/app/details/CMR-HE20_4000-00195421
APA
Food and Drug Administration, Health and Human Services Department.
(2024, April 19).
Performance Report to Congress: Biosimilar User Fee Act FY 2023.
[Government].
Health and Human Services Department, Food and Drug Administration.
https://www.govinfo.gov/app/details/CMR-HE20_4000-00195421
MLA
Food and Drug Administration, Health and Human Services Department.
Performance Report to Congress: Biosimilar User Fee Act FY 2023.
Health and Human Services Department, Food and Drug Administration,
(19 Apr 2024),
https://www.govinfo.gov/app/details/CMR-HE20_4000-00195421
Bluebook
Food and Drug Administration, Health and Human Services Department, Performance Report to Congress: Biosimilar User Fee Act FY 2023, GovInfo, (April 19, 2024),
https://www.govinfo.gov/app/details/CMR-HE20_4000-00195421
